•The European Commission announced Wednesday it is seeking feedback on commitments offered by Sanofi to address concerns over potential breaches of competition rules.
•The investigation pertains to a flu vaccine marketing campaign suspected of involving anti-competitive behavior.
•The FDA accepted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to include infants aged 3 to 24 months for atopic dermatitis treatment.
•The FDA has set a PDUFA target action date of February 23, 2027, for the application decision.
